Abstract
Evidence was presented that 9-E-6-MP is dealkylated by the human in amounts adequate to provide enough 6-MP to explain the effectiveness of this drug when it is administered to chronic granulocytic leukemia patients. 9-E-6-MP does not serve as substrate for xanthine oxidase, nor purine nucleoside phosphorylase. The possibility that the enzyme responsible for dealkylation is present in human bone marrow or neutro-phils is discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
